Skip to main content
. 2010 Mar;31(3):401–409. doi: 10.3174/ajnr.A1753

Fig 1.

Fig 1.

Gd-DOTA (Dotarem; Guerbet, Aulnay-sous-Bois, France) and Gd-DTPA (Magnevist; Schering, Berlin, Germany). Two examples of clinically used Gd3+ poly(amino carboxylate) complexes. All other approved Gd3+-based contrast agents are derivatives of Gd-DOTA or Gd-DTPA.